Eli Lilly and Company (NYSE:LLY) Shares Acquired by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,606 shares of the company's stock after buying an additional 897 shares during the quarter. Congress Wealth Management LLC DE's holdings in Eli Lilly and Company were worth $37,525,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Garner Asset Management Corp raised its position in Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after buying an additional 12 shares during the last quarter. FWG Holdings LLC grew its position in Eli Lilly and Company by 0.6% during the 4th quarter. FWG Holdings LLC now owns 2,023 shares of the company's stock worth $1,640,000 after purchasing an additional 12 shares during the period. Morling Financial Advisors LLC boosted its stake in shares of Eli Lilly and Company by 4.7% in the fourth quarter. Morling Financial Advisors LLC now owns 266 shares of the company's stock worth $205,000 after buying an additional 12 shares during the last quarter. GSG Advisors LLC raised its position in Eli Lilly and Company by 3.2% during the fourth quarter. GSG Advisors LLC now owns 425 shares of the company's stock valued at $328,000 after acquiring an additional 13 shares in the last quarter. Finally, IMZ Advisory Inc lifted its holdings in Eli Lilly and Company by 2.0% in the fourth quarter. IMZ Advisory Inc now owns 662 shares of the company's stock valued at $511,000 after acquiring an additional 13 shares during the period. Institutional investors own 82.53% of the company's stock.

Remove Ads

Eli Lilly and Company Price Performance

LLY traded down $4.62 during trading on Thursday, reaching $822.14. The company's stock had a trading volume of 2,126,892 shares, compared to its average volume of 3,153,218. The company has a market cap of $779.52 billion, a price-to-earnings ratio of 70.21, a PEG ratio of 1.40 and a beta of 0.34. The firm has a fifty day simple moving average of $842.43 and a two-hundred day simple moving average of $837.43. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has initiated a share repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board believes its shares are undervalued.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Bank of America reiterated a "buy" rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Morgan Stanley set a $1,146.00 price target on Eli Lilly and Company in a research report on Thursday, March 6th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Finally, Citigroup dropped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $1,009.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.